Staying Diversified, Bayer Sees Opportunities In Digital Innovation
Pharma Has Missed Digital Health Potential
Despite its Monsanto woes, Bayer is sticking with its diversified portfolio, and is branching out into patient-facing digital health services.
You may also be interested in...
The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.
Janssen’s hemato-oncology success rolls on with impressive new overall survival data